Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

SVB Leerink Maintains Outperform on Design Therapeutics, Lowers Price Target to $22

SVB Leerink analyst Joseph Schwartz maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform and lowers the price target from $30 to $22.

byBenzinga Newsdesk

December 9, 2022

1 minute read

SVB Leerink analyst Joseph Schwartz maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform and lowers the price target from $30 to $22.

Keybanc Maintains Overweight on American Tower, Lowers Price Target to $286

By Benzinga Newsdesk

Today, 11:37 AM

Keybanc analyst Brandon Nispel maintains American Tower (NYSE:AMT) with a Overweight and lowers the price target from $311 to $286.

AMT

AMSC Wins $21M In New Energy Power System Orders

By Benzinga Newsdesk

Today, 11:37 AM

AMSC® (NASDAQ:AMSC), a leading system provider of megawatt-scale power resiliency solutions that orchestrate the rhythm and harmony of power on the grid™ and protect and expand the capability of

AMSC

Star Bulk Carriers Stock Gains On Q2 Earnings Beat, Declares Dividend, Plans $50M Share Repurchase

By Akanksha

Today, 11:37 AM

Star Bulk Carriers Corp. (NASDAQ:SBLK) reported second-quarter voyage revenue growth of 113.1% year-over-year to $311.41 million, beating the consensus of $296.110…

SBLK

Johnson & Johnson, Distributors Reach $590M Opioid Settlement For Tribe Claims: Report

By Vandana Singh

Today, 11:37 AM

Johnson & Johnson (NYSE: JNJ) and the three U.S.

ABC

SVB Leerink Maintains Outperform on Design Therapeutics, Lowers Price Target to $22

Related Posts

Keybanc Maintains Overweight on American Tower, Lowers Price Target to $286

AMSC Wins $21M In New Energy Power System Orders

Star Bulk Carriers Stock Gains On Q2 Earnings Beat, Declares Dividend, Plans $50M Share Repurchase

Johnson & Johnson, Distributors Reach $590M Opioid Settlement For Tribe Claims: Report